Duration of pemetrexed maintenance therapy with or without pembrolizumab is associated with risk of renal toxicity in patients with metastatic nonsquamous NSCLC.

Tejas Patil,Yunan Nie,Junxiao Hu,Erin L. Schenk,Jose Maria Pacheco,William T. Purcell,Paul A. Bunn,D. Ross Camidge

Duration of pemetrexed maintenance therapy with or without pembrolizumab is associated with risk of renal toxicity in patients with metastatic nonsquamous NSCLC.

2021

Tejas Patil
Yunan Nie
Junxiao Hu
Erin L. Schenk
Jose Maria Pacheco
William T. Purcell
Paul A. Bunn
D. Ross Camidge

e21205Background: Use of maintenance pemetrexed with pembrolizumab is the standard of care among patients with metastatic nonsquamous NSCLC without EGFR or ALK alterations treated with the KEYNOTE-...

Keywords:

Internal medicine
Medicine
Pemetrexed
Pembrolizumab
Toxicity
in patient
Oncology
standard of care
Maintenance therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations